Special Issue "Uremic Toxins and Drugs"

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Uremic Toxins".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editors

Prof. Dr. Sophie Liabeuf
E-Mail Website
Guest Editor
Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France and EA7517 Unit— MP3CV, UPJV University, Amiens, France
Interests: uremic toxins; pharmaco-epidemiology, cardiovascular; vascular calcification
Special Issues and Collections in MDPI journals
Dr. Youssef Bennis
E-Mail Website
Guest Editor
Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France and EA7517 Unit— MP3CV, UPJV University, Amiens, France
Interests: uremic toxins; cardiovascular calcifications; inflammation; pharmacokinetics

Special Issue Information

Dear Colleagues,

Patients with chronic kidney disease (CKD) are at a high risk of morbidity and mortality. Kidney function decline in CKD is associated with the accumulation of compounds which under normal conditions are cleared by healthy kidneys. If they interfere with biological/biochemical functions, these solutes are called uremic toxins. Uremic toxins have been classified into three classes depending on molecular weight and protein binding:  small water-soluble molecules, middle molecules, and protein bound molecules. Several groups of authors have shown that high serum levels of a variety of uremic toxins are associated with mortality and cardiovascular and renal events. Thus, these toxins are potential therapeutic targets. Research on pharmacological treatment to reduce uremic toxins levels or prevent their deleterious effects are crucial.

In addition to direct tissue toxicity, their negative impact could also result from changes in the pharmacokinetic/pharmacodynamic activity of numerous drugs. Recent data have also suggested a potential impact of drugs on levels of uremic toxins.

The focus of this Special Issue of Toxins will include original research articles and reviews on uremic toxins and drugs that could present two different aspects: i) pharmacological tools to reduce uremic toxins levels or prevent their deleterious effects and ii) potential interactions between uremic toxins and drugs.

Prof. Dr. Sophie Liabeuf
Dr. Youssef Bennis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • uremic toxins
  • drugs
  • therapeutic target
  • interaction
  • AhR
  • OATs
  • gut microbiota
  • inflammation
  • oxidative stress
  • cell senescence
  • pharmacokinetics

Published Papers

This special issue is now open for submission.
Back to TopTop